Atlas Trials

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Clinical trial NCT02213926 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02213926
Sponsor
Acerta Pharma BV
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Mantle Cell Lymphoma (MCL)
Start date
2015-03-02
Primary completion
2020-12-04
Enrollment
124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.